At Envoya, we use a two-part AI platform—one generates precise peptides to target specific cells, and the other selects ideal polymer compositions for encapsulating various genetic payloads. Drawing on receptor binding data, polymer characteristics, and wet-lab results, each design is refined to enhance stability, minimize toxicity, and improve targeting. By continuously learning from real-world testing, our system accelerates development cycles and helps partners reach meaningful breakthroughs faster.
This synergy between advanced computation and polymer science is what sets us apart. Our integrated AI approach significantly cuts down on dead ends and streamlines development. Whether you’re an early-stage researcher or a large-scale developer, the outcome of Envoya’s unique blend of AI innovation and polymer expertise is clear: greater efficiency, lower R&D costs, and a more direct path to effective gene therapies that change patient lives on a global scale.
Tell us your desired siRNA sequence and cell target for custom Envoyer Nanoparticles.
Our Envoyer nanoparticles can also efficiently deliver mRNA to any cell type.
Our Envoyer nanoparticles can encapsulate over 10 kbp of plasmid DNA.
CRISPR-Cas9 is a powerful tool. From ds & ss-cutting to base-editing, knock-ins/outs, CRISPRi, and more, the large payloads enabled by Envoyer nanoparticles let you design even greater experiments.
Our Biopuzzle AI system generates de novo peptide ligands for targeting our Envoyer nanoparticles to your cell or tissue of interest.
Envoya pre-made nanoparticles include GFP markers for mRNA & DNA, a CRISPR genome-editing kit, and an siRNA knock-down kit. Our kits work in any murine & human cell lines.
We offer a range of customizable nanoparticle solutions tailored to specific research and therapeutic needs. Our products are designed to deliver various genetic materials, including mRNA and plasmid DNA, with high efficiency and minimal toxicity. By partnering with us, researchers and clinicians can access cutting-edge delivery systems that enhance the success of their gene therapy endeavors.